
  
    
      
        Background_NNP
        Statins_NNP ,_, potent_JJ compounds_NNS that_WDT inhibit_VBP cholesterol_NN
        synthesis_NN in_IN the_DT liver_NN by_IN blocking_VBG
        3_CD -_: hydroxy-_NN 3_CD -_: methylglutaryl_NN coenzyme_NN A_DT (_( HMG-CoA_NNP )_) ,_, have_VBP been_VBN
        reported_VBN to_TO induce_VB osteoblast_NN activity_NN and_CC lead_VB to_TO bone_NN
        formation_NN ,_, both_DT in_IN tissue_NN culture_NN and_CC in_IN rats_NNS and_CC mice_NNS [_NN 1_CD
        2_CD 3_CD 4_CD 5_CD 6_CD ]_NN ._. These_DT findings_NNS ,_, if_IN confirmed_VBD and_CC extended_VBN to_TO
        include_VB humans_NNS ,_, have_VBP the_DT potential_NN to_TO introduce_VB immediate_JJ
        new_JJ treatment_NN options_NNS to_TO patients_NNS with_IN low_JJ bone_NN mass_NN and_CC
        osteoporosis_NNS ._. Such_JJ treatment_NN is_VBZ readily_RB available_JJ ,_, since_IN an_DT
        estimated_VBN 3_CD million_CD patients_NNS in_IN the_DT US_NNP alone_RB take_VBP statins_NNS
        daily_JJ to_TO treat_VB hyperlipidemia_NN with_IN few_JJ side_NN effects_NNS [_NN 7_CD ]_NN ._.
        Osteoporosis_NNP is_VBZ increasingly_RB recognized_VBN as_IN an_DT eminent_JJ
        public_JJ health_NN problem_NN ,_, as_IN the_DT mean_JJ age_NN of_IN populations_NNS in_IN
        most_JJS Western_JJ countries_NNS increases_NNS and_CC costs_NNS related_VBN to_TO
        osteoporosis_NNS are_VBP expected_VBN to_TO grow_VB six-fold_RB by_IN the_DT year_NN 2040_CD
        [_NN 8_CD ]_NN ._. Data_NNP from_IN the_DT National_NNP Health_NNP and_CC Nutrition_NNP
        Examination_NNP Survey_NNP ,_, using_VBG a_DT definition_NN of_IN osteoporosis_NNS
        developed_VBN by_IN the_DT World_NNP Health_NNP Organization_NNP ,_, estimate_NN that_IN
        in_IN the_DT United_NNP States_NNPS up_IN to_TO 20_CD %_NN of_IN Caucasian_NNP women_NNS over_IN 50_CD
        have_VBP osteoporosis_NNS and_CC up_IN to_TO 50_CD %_NN have_VBP low_JJ bone_NN mass_NN ._.
        Non-caucasian_NNP women_NNS and_CC men_NNS tend_VBP to_TO have_VB lower_JJR rates_NNS of_IN
        osteoporosis_NNS but_CC contribute_VB up_IN to_TO 25_CD %_NN of_IN the_DT fractures_NNS
        annually_RB [_NN 9_CD ]_NN ._.
        The_DT only_JJ bone_NN anabolic_JJ agent_NN known_VBN to_TO increase_VB bone_NN
        mineral_NN density_NN in_IN both_DT animal_NN models_NNS and_CC clinical_JJ settings_NNS
        is_VBZ human_JJ parathyroid_NN hormone_NN 1_CD -_: 34_CD (_( PTH_NNP )_) ,_, which_WDT has_VBZ recently_RB
        been_VBN approved_VBN by_IN the_DT FDA_NNP in_IN patients_NNS with_IN advance_NN
        osteoporosis_NNS [_NN 10_CD ]_NN ._. Bone-related_NNP basic_JJ and_CC clinical_JJ
        research_NN has_VBZ been_VBN searching_VBG intensively_RB for_IN alternative_NN
        anabolic_JJ agents_NNS for_IN the_DT treatment_NN of_IN osteoporosis_NNS ._.
        Due_JJ to_TO the_DT potential_JJ clinical_JJ impact_NN of_IN statins_NNS as_IN a_DT
        treatment_NN option_NN for_IN patients_NNS with_IN low_JJ bone_NN mass_NN and_CC
        osteoporosis_NNS ,_, it_PRP is_VBZ essential_JJ to_TO evaluate_VB its_PRP$ anabolic_JJ
        activity_NN in_IN several_JJ 
        in_IN vitro_NN and_CC experimental_JJ animal_NN
        models_NNS ._. We_PRP have_VBP recently_RB reported_VBN the_DT anabolic_JJ action_NN of_IN
        PTH_NNP in_IN an_DT ovariectomized_JJ (_( OVX_NNP )_) Swiss-_NNP Webster_NNP mouse_NN model_NN ,_,
        which_WDT like_IN the_DT rat_NN model_NN ,_, displays_VBZ a_DT substantial_JJ amount_NN of_IN
        trabecular_NN bone_NN in_IN its_PRP$ femoral_NN metaphyses_NNS and_CC a_DT
        quantifiable_JJ loss_NN of_IN bone_NN following_VBG OVX_NNP [_NN 11_CD ]_NN ._. The_DT aim_NN of_IN
        this_DT study_NN was_VBD to_TO investigate_VB the_DT effect_NN of_IN simvastatin_NN on_IN
        the_DT microarchitecture_NN of_IN bone_NN in_IN an_DT established_VBN mouse_NN model_NN
        of_IN osteoporosis_NNS ,_, and_CC compare_VB its_PRP$ anabolic_JJ action_NN with_IN PTH_NNP ._.
        We_PRP also_RB verified_VBN the_DT presence_NN of_IN systemically_RB administered_VBN
        simvastatin_NN in_IN the_DT mouse_NN serum_NN ,_, as_IN this_DT has_VBZ previously_RB not_RB
        been_VBN reported_VBN and_CC is_VBZ likely_JJ to_TO be_VB of_IN critical_JJ importance_NN
        when_WRB evaluating_VBG the_DT effect_NN of_IN simvastatin_NN on_IN bone_NN ._.
      
      
        Methods_NNP
        
          Animals_NNS
          72_CD eleven-week-old_JJ virgin_JJ female_JJ Swiss-_NNP Webster_NNP mice_NNS
          were_VBD purchased_VBN from_IN Taconic_NNP Farms_NNP (_( Germantown_NNP ,_, NY_NNP )_) and_CC
          maintained_VBN at_IN the_DT animal_NN research_NN facility_NN at_IN the_DT Beth_NNP
          Israel_NNP Deaconess_NNP Medical_NNP Center_NNP ._. Animals_NNS were_VBD fed_VBN Purina_NNP
          Formulab_NNP Diet_NNP containing_VBG 1_CD %_NN Ca_MD (_( Formulab_NNP ,_, Richmond_NNP ,_, IN_IN )_)
          and_CC water_NN 
          ad_NN libitum_NN throughout_IN the_DT
          experiment_NN ._. Mice_NNS were_VBD sacrificed_JJ by_IN CO_NNP 
          2_CD inhalation_NN ._.
        
        
          Experimental_NNP protocol_NN
          
            Micro-computed_NNP tomography_NN analysis_NN
            For_IN a_DT detailed_VBN qualitative_JJ and_CC quantitative_JJ 3_CD -_: D_NNP
            evaluation_NN ,_, whole_JJ femoral_NN bones_NNS were_VBD examined_VBN by_IN a_DT
            desktop_NN μCT_NN system_NN (_( μCT_NN 20_CD ,_, Scanco_NNP Medical_NNP AG_NNP ,_,
            Bassersdorf_NNP ,_, Switzerland_NNP )_) equipped_VBN with_IN a_DT 10_CD μm_NN focal_JJ
            spot_NN microfocus_JJ X-_NNP ray_NN tube_NN as_IN a_DT source_NN [_NN 12_CD ]_NN ._. For_IN
            image_NN acquisition_NN ,_, the_DT specimen_NN was_VBD mounted_VBN on_IN a_DT
            turntable_JJ shifted_VBN automatically_RB in_IN an_DT axial_NN direction_NN
            over_IN 216_CD °_NN (_( 180_CD °_NN plus_CC half_JJ fan_NN angle_NN on_IN either_DT side_NN )_) ,_,
            taking_VBG 600_CD projections_NNS ._. To_TO scan_VB the_DT entire_JJ femoral_NN
            width_NN (_( 3_CD ._. 4_LS -_: 5_CD ._. 1_LS mm_NN )_) ,_, including_VBG the_DT femoral_NN head_NN ,_, a_DT total_NN
            of_IN 100_CD -_: 150_CD micro-tomographic_JJ slices_NNS were_VBD acquired_VBN at_IN a_DT
            34_CD μm_NN slice_NN increment_NN ._. CT_NNP images_NNS were_VBD reconstructed_VBN in_IN
            512_CD ×_NN 512_CD pixel_NN matrices_NNS using_VBG a_DT standard_JJ
            convolution-backprojection_JJ procedure_NN with_IN a_DT Shepp_NNP and_CC
            Logan_NNP filter_NN ._. Images_NNP were_VBD stored_VBN in_IN 3_CD -_: D_NNP arrays_NNS with_IN an_DT
            isotropic_JJ voxel_NN size_NN of_IN 34_CD μm_NN ._. A_DT constrained_VBN 3_CD -_: D_NNP
            Gaussian_NNP filter_NN was_VBD used_VBN to_TO partly_RB suppress_VB the_DT noise_NN
            in_IN the_DT volumes_NNS and_CC the_DT mineralized_JJ tissue_NN was_VBD segmented_JJ
            from_IN soft_JJ tissues_NNS by_IN a_DT global_JJ thresholding_VBG procedure_NN [_NN
            13_CD ]_NN ._. Morphometric_NNP parameters_NNS were_VBD determined_VBN using_VBG a_DT
            direct_JJ 3_CD -_: D_NNP approach_NN [_NN 14_CD ]_NN in_IN three_CD different_JJ
            pre-selected_JJ analysis_NN regions_NNS :_: whole_JJ bone_NN (_( including_VBG
            the_DT articular_NN ends_VBZ )_) ,_, secondary_JJ spongiosa_NN in_IN the_DT distal_NN
            metaphysis_NNS ,_, and_CC diaphyseal_NN cortical_JJ bone_NN ._. Parameters_NNP
            determined_VBD in_IN the_DT metaphyseal_NN trabecular_NN bone_NN included_VBD
            bone_NN volume_NN density_NN (_( BV_NNP /_NN TV_NN )_) ,_, bone_NN surface_NN density_NN
            (_( BS_NNP /_NN TV_NN )_) ,_, trabecular_NN number_NN (_( Tb_NNP ._. N_NNP )_) ,_, trabecular_NN thickness_NN
            (_( Tb_NNP ._. Th_NNP )_) ,_, trabecular_NN spacing_VBG (_( Tb_NNP ._. Sp_NNP )_) and_CC connectivity_NN
            density_NN ._. Cortical_NNP volume_NN (_( TV_NN )_) ,_, percent_NN marrow_NN volume_NN
            (_( %_NN MV_NNP )_) and_CC cortical_JJ thickness_NN (_( Ct_NNP ._. Th_NNP )_) were_VBD assessed_VBN in_IN a_DT
            1_CD mm-thick_JJ slab_NN in_IN the_DT mid-diaphysis_JJ ._.
          
          
            Mass_NNP Spectrometry_NNP
            Bond_NNP Elut_NNP C_NNP 
            8_CD SPE_NNP cartridges_NNS (_( 1_CD ml_NN /_NN 100_CD mg_NN )_) were_VBD
            purchased_VBN from_IN Varian_NNP /_NN Sample_NNP Preparation_NNP Products_NNPS
            (_( Harbor_NNP City_NNP ,_, CA_NNP ,_, USA_NNP )_) ._. ESI-MS_NNP (_( electrospray_NN ionization_NN
            mass_NN spectrometry_NN )_) were_VBD recorded_VBN on_IN a_DT Micromass_NNP
            Platform_NNP LCZ_NNP system_NN equipped_VBN with_IN an_DT electrospray_NN
            ionization_NN source_NN and_CC a_DT Waters_NNP 2690_CD Separation_NNP Module_NNP ._.
            For_IN analytical_JJ RP-HPLC_NNP (_( Reverse-phase_NNP high_JJ performance_NN
            liquid_JJ chromatography_NN Vydac_NNP C_NNP 18_CD columns_NNS were_VBD used_VBN ;_: the_DT
            solvent_JJ system_NN used_VBN included_VBD Water_NNP /_NN TFA_NNP (_( 1000_CD :_: 1_CD ,_, eluent_NN
            A_DT )_) and_CC Acetonitrile_NNP /_NN TFA_NNP (_( 1000_CD :_: 1_CD ,_, eluent_NN B_NNP )_) ._. Linear_NNP
            elution-gradient_JJ was_VBD used_VBN (_( "_'' Waters_NNP Gradient_NNP 6_CD "_'' ,_, t_NN =_SYM 0_CD
            min_NN ,_, 10_CD %_NN B_NNP ;_: t_NN =_SYM 1_CD min_NN ,_, 45_CD %_NN B_NNP ;_: 
            t_NN =_SYM 21_CD min_NN ,_, 60_CD %_NN B_NNP ;_: t_NN =_SYM 26_CD 100_CD %_NN
            MeOH_NNP ;_: t_NN =_SYM 35_CD min_NN ,_, 10_CD %_NN B_NNP )_) ._. Flow_NNP rates_NNS were_VBD 0_CD ._. 2_CD ml_NN /_NN min_NN
            and_CC the_DT detection_NN wavelengths_NNS were_VBD set_VBN to_TO 220_CD and_CC 240_CD
            nm_NN ._.
          
          
            Sample_NNP preparation_NN
            All_DT sample_NN preparation_NN procedures_NNS were_VBD carried_VBN out_IN
            in_IN an_DT ice-water_JJ bath_NN ._. Stock_NN solution_NN of_IN simvastatin_NN was_VBD
            prepared_VBN in_IN ethanol_NN and_CC of_IN simvastatin_NN hydroxy_NN acid_NN in_IN
            methanol-water_JJ (_( 90_CD :_: 10_CD )_) at_IN 4_CD °_NN C_NNP ._. Calibration_NNP standards_NNS
            were_VBD prepared_VBN fresh_JJ for_IN each_DT analysis_NN ,_, by_IN dilutions_NNS in_IN
            methanol-water_JJ (_( 70_CD :_: 30_CD )_) ._. The_DT doses_NNS of_IN the_DT standards_NNS at_IN
            the_DT respective_JJ points_NNS on_IN the_DT calibration_NN graphs_NNS were_VBD 1_CD ,_,
            10_CD ,_, 30_CD ,_, 60_CD ,_, 100_CD ,_, 150_CD ng_NN ._. Recovery_NNP of_IN simvastatin_NN and_CC of_IN
            simavastatin_NN hydroxy_NN acid_NN from_IN mouse_NN plasma_NN following_VBG
            the_DT extraction_NN procedure_NN below_IN ,_, was_VBD assessed_VBN by_IN
            comparison_NN of_IN samples_NNS at_IN three_CD doses_NNS (_( 30_CD ,_, 80_CD and_CC 150_CD
            ng_NN )_) ,_, which_WDT were_VBD used_VBN to_TO spike_NN 0_CD ._. 1_CD ml_NN mouse_NN plasma_NN
            followed_VBN by_IN extraction_NN and_CC injection_NN into_IN LC-MS_NNP ,_, to_TO
            similar_JJ doses_NNS directly_RB injected_VBN to_TO the_DT LC-MS_NNP ._. The_DT
            quantitation_NN was_VBD based_VBN on_IN integration_NN of_IN the_DT area_NN under_IN
            the_DT respective_JJ peaks_NNS in_IN the_DT UV_NNP spectra_NN obtained_VBN at_IN 240_CD
            nm_NN (_( approximately_RB the_DT λ_NN 
            max_NN for_IN both_DT simvastatin_NN and_CC
            simavastatin_NN hydroxy_NN acid_NN )_) ._. Each_DT of_IN the_DT samples_NNS from_IN
            the_DT 
            in_IN vivo_NN tests_NNS (_( 0_CD ._. 15_CD ml_NN )_) ,_, or_CC the_DT
            recovery_NN test_NN above_IN ,_, was_VBD diluted_VBN with_IN 0_CD ._. 4_CD ml_NN of_IN water_NN
            prior_RB to_TO extraction_NN ._.
          
          
            Extraction_NNP procedure_NN
            This_DT procedure_NN was_VBD based_VBN on_IN the_DT previously_RB published_VBN
            protocol_NN by_IN Wu_NNP et_CC al_NN ._. [_NN 15_CD ]_NN ,_, implementing_VBG minor_JJ
            modifications_NNS ._. Each_DT solid-phase_JJ extraction_NN cartridge_NN (_( 1_CD
            ml_NN /_NN 100_CD mg_NN )_) was_VBD conditioned_VBN with_IN Methanol-water_NNP (_( 50_CD :_: 50_CD )_) ._.
            The_DT diluted_VBN sample_NN (_( see_VB Sample_NNP preparation_NN )_) was_VBD loaded_VBN
            on_IN to_TO each_DT cartridge_NN ,_, followed_VBN by_IN low_JJ vacuum_NN (_( 1_CD min_NN )_) ,_,
            and_CC each_DT cartridge_NN was_VBD subsequently_RB washed_VBN with_IN 1_CD ml_NN H_NNP 
            2_CD O_NNP ,_, 1_CD ml_NN 5_CD %_NN formic_JJ acid_NN ,_, 1_CD ml_NN H_NNP 
            2_CD O_NNP and_CC dried_VBD for_IN 1_CD min_NN ._. Each_DT
            cartridge_NN was_VBD then_RB eluted_JJ with_IN 1_CD ml_NN of_IN methanol-water_JJ
            (_( 70_CD :_: 30_CD )_) solution_NN and_CC with_IN 1_CD ml_NN of_IN acetonitrile_NN ,_,
            followed_VBN by_IN low_JJ vacuum_NN (_( 1_CD min_NN )_) ._. The_DT combined_VBN eluates_NNS
            were_VBD evaporated_VBN to_TO dryness_NN in_IN a_DT SpeedVac_NNP at_IN 45_CD °_NN C_NNP ._. The_DT
            dry_JJ residues_NNS were_VBD reconstituted_JJ in_IN 100_CD μl_NN of_IN ammonium_NN
            acetate_NN (_( 10_CD mm_NN ,_, pH_NN 4_CD ._. 0_CD )_) -_: acetonitrile_NN (_( 30_CD :_: 70_CD )_) ._. The_DT
            reconstituted_JJ extracts_NNS were_VBD transferred_VBN into_IN
            autosampler_NN vials_NNS and_CC 50_CD μl_NN of_IN each_DT sample_NN were_VBD
            injected_VBN on_IN to_TO the_DT LC_NNP column_NN (_( equivalent_JJ to_TO 75_CD μl_NN of_IN
            plasma_NN sample_NN )_) ._.
          
          
            Osteocalcin_NNP assay_NN
            Blood_NNP was_VBD sampled_VBN prior_RB to_TO sacrifice_VB to_TO determine_VB
            serum_NN levels_NNS of_IN osteocalcin_NN (_( OC_NNP )_) ._. Serum_NNP intact_JJ OC_NNP was_VBD
            measured_VBN by_IN a_DT two-site_JJ immunoradiometric_JJ assay_NN (_( IRMA_NNP
            kit_NN ,_, Immutopics_NNP Inc_NNP ._. ,_, San_NNP Clemente_NNP ,_, CA_NNP )_) against_IN the_DT
            mid-region_JJ C-_NNP terminal_NN and_CC amino-terminal_JJ position_NN of_IN
            mouse_NN OC_NNP with_IN a_DT known_VBN sensitivity_NN of_IN 0_CD ._. 1_CD ng_NN /_NN mL_NN ._. Intra-_NNP
            and_CC interassay_NN CVs_NNP were_VBD 2_CD ._. 3_CD %_NN and_CC 4_CD ._. 4_CD %_NN ,_,
            respectively_RB ._.
          
          
            Statistical_NNP Analysis_NNP
            A_DT power_NN analysis_NN was_VBD conducted_VBN in_IN planning_VBG the_DT
            experiments_NNS to_TO determine_VB the_DT sufficient_JJ number_NN of_IN mouse_NN
            femurs_NNS in_IN this_DT investigation_NN ._. A_DT total_JJ sample_NN size_NN of_IN 72_CD
            animals_NNS (_( n_NN =_SYM 9_CD per_IN treatment_NN condition_NN )_) was_VBD required_VBN to_TO
            provide_VB 90_CD %_NN power_NN (_( α_NN =_SYM 0_CD ._. 05_CD ,_, β_NN =_SYM 0_CD ._. 1_LS )_) to_TO detect_VB a_DT
            significant_JJ difference_NN of_IN 1_CD standard_JJ deviation_NN (_( effect_NN
            size_NN =_SYM 1_CD ._. 0_CD )_) between_IN the_DT Simvastatin_NNP ,_, PTH_NNP ,_, OVX_NNP ,_, and_CC SHAM_NNP
            treatments_NNS with_IN respect_NN to_TO each_DT trabecular_NN and_CC cortical_JJ
            bone_NN parameter_NN using_VBG one-way_JJ analysis_NN of_IN variance_NN
            (_( ANOVA_NNP )_) with_IN a_DT two-tailed_JJ significance_NN level_NN of_IN 0_CD ._. 05_CD ._.
            Sample_NNP size_NN calculations_NNS were_VBD determined_VBN using_VBG the_DT
            nQuery_NN Advisor_NNP software_NN program_NN (_( version_NN 4_CD ._. 0_CD ,_,
            Statistical_NNP Solutions_NNPS ,_, Boston_NNP ,_, MA_NNP )_) ._.
            All_DT continuous_JJ variables_NNS were_VBD checked_VBN for_IN normality_NN
            using_VBG the_DT Kolmogorov-_NNP Smirnov_NNP goodness-of-fit_JJ test_NN and_CC
            were_VBD found_VBN to_TO follow_VB a_DT normal_JJ distribution_NN closely_RB [_NN 16_CD
            ]_NN ._. Therefore_RB ,_, results_NNS are_VBP reported_VBN in_IN terms_NNS of_IN means_NNS ±_NN
            standard_JJ deviation_NN (_( SD_NNP )_) ._. Treatment_NNP groups_NNS were_VBD compared_VBN
            with_IN respect_NN to_TO trabecular_NN and_CC cortical_JJ bone_NN parameters_NNS
            obtained_VBN by_IN μCT_NN by_IN use_NN of_IN analysis_NN of_IN variance_NN (_( ANOVA_NNP )_)
            with_IN the_DT Fisher_NNP least_JJS significant_JJ difference_NN (_( LSD_NNP )_)
            method_NN for_IN 
            post-hoc_JJ multiple_JJ testing_NN [_NN 17_CD ]_NN
            ._. A_DT two-tailed_JJ value_NN of_IN p_NN <_NN 0_CD ._. 05_CD was_VBD established_VBN as_IN
            the_DT criterion_NN for_IN statistical_JJ significance_NN ._. Statistical_NNP
            analysis_NN was_VBD performed_VBN using_VBG the_DT SPSS_NNP (_( version_NN 11_CD ._. 0_CD ,_,
            SPSS_NNP Inc_NNP ._. ,_, Chicago_NNP ,_, IL_NNP )_) and_CC SAS_NNP (_( version_NN 6_CD ._. 12_CD ,_, SAS_NNP
            Institute_NNP ,_, Cary_NNP ,_, NC_NNP )_) software_NN packages_NNS ._.
          
        
      
      
        Results_NNS
        
          Effects_NNPS of_IN OVX_NNP on_IN bone_NN loss_NN
          Consistent_NNP with_IN the_DT findings_NNS in_IN our_PRP$ recent_JJ study_NN [_NN 11_CD
          ]_NN ,_, μCT_NN analyses_NNS of_IN femoral_NN trabecular_NN and_CC cortical_JJ bone_NN
          showed_VBD little_JJ change_NN over_IN the_DT duration_NN of_IN the_DT study_NN in_IN
          any_DT of_IN the_DT structural_JJ variables_NNS for_IN SHAM_NNP OVX_NNP
          Swiss-_NNP Webster_NNP mice_NNS (_( groups_NNS T_NN 1_CD /_NN SHAM_NNP ,_, T_NN 5_CD /_NN SHAM_NNP ,_, T_NN 13_CD /_NN SHAM_NNP )_) ._.
          OVX_NNP mice_NNS demonstrated_VBN significantly_RB lower_JJR trabecular_NN bone_NN
          volume_NN density_NN (_( BV_NNP /_NN TV_NN )_) compared_VBN to_TO SHAM_NNP controls_NNS at_IN 1_CD
          week_NN (_( 15_CD ±_NN 6_CD %_NN vs_NNS ._. 26_CD ±_NN 5_CD %_NN ,_, 
          P_NN <_NN 0_CD ._. 001_CD )_) 5_CD weeks_NNS (_( 5_CD ±_NN 3_CD %_NN vs_NNS ._.
          28_CD ±_NN 12_CD %_NN ,_, 
          P_NN <_NN 0_CD ._. 001_CD )_) ,_, and_CC showed_VBD a_DT
          reduction_NN of_IN 85_CD %_NN at_IN 13_CD weeks_NNS (_( 5_CD ±_NN 4_CD %_NN vs_NNS ._. 34_CD ±_NN 11_CD %_NN ,_, 
          P_NN <_NN 0_CD ._. 001_CD ,_, Table_NNP 1_LS )_) ._. In_IN
          addition_NN ,_, trabecular_NN thickness_NN ,_, spacing_VBG and_CC number_NN were_VBD
          significantly_RB different_JJ in_IN OVX_NNP mice_NNS compared_VBN to_TO SHAM_NNP
          controls_NNS at_IN 5_CD and_CC 13_CD weeks_NNS (_( all_DT 
          P_NN <_NN 0_CD ._. 001_CD )_) ._. However_RB ,_, cortical_JJ
          parameters_NNS including_VBG total_JJ volume_NN ,_, marrow_NN volume_NN /_NN total_JJ
          volume_NN ,_, and_CC thickness_NN were_VBD not_RB significantly_RB different_JJ
          between_IN OVX_NNP and_CC SHAM_NNP controls_NNS throughout_IN the_DT 13_CD -_: week_NN
          study_NN course_NN (_( all_DT 
          P_NN >_NN 0_CD ._. 20_CD ,_, Table_NNP 1_LS )_) ._.
        
        
          Effect_NN of_IN PTH_NNP and_CC SVS_NNP treatment_NN on_IN bone_NN
          At_IN 13_CD weeks_NNS ,_, trabecular_NN bone_NN volume_NN density_NN (_( BV_NNP /_NN TV_NN )_) in_IN
          mice_NNS treated_VBN with_IN PTH_NNP alone_RB (_( T_NN 13_CD /_NN OVX_NNP /_NN PTH_NNP )_) was_VBD 4_CD ._. 2_CD -_: fold_VB
          higher_JJR than_IN vehicle-treated_JJ animals_NNS (_( T_NN 13_CD /_NN OVX_NNP /_NN VEH_NNP )_) (_( Table_NNP
          2_LS )_) ._. PTH_NNP treatment_NN was_VBD associated_VBN with_IN significant_JJ
          increases_NNS in_IN Tb_NNP ._. Th_NNP and_CC Tb_NNP ._. N_NNP as_RB well_RB as_IN an_DT expected_VBN
          decrease_NN in_IN Tb_NNP ._. Sp_NNP ._. In_IN addition_NN ,_, significant_JJ differences_NNS
          in_IN cortical_JJ %_NN MV_NNP /_NN TV_NN and_CC thickness_NN were_VBD observed_VBN at_IN 13_CD
          weeks_NNS (_( 
          P_NN <_NN 0_CD ._. 01_CD ,_, Table_NNP 2_LS )_) ._.
          In_IN comparison_NN ,_, trabecular_NN BV_NNP /_NN TV_NN in_IN SVS-treated_NNP animals_NNS
          at_IN 13_CD weeks_NNS (_( T_NN 13_CD /_NN OVX_NNP /_NN SVS_NNP )_) was_VBD not_RB significantly_RB increased_VBN
          over_IN that_DT observed_VBD in_IN vehicle-treated_JJ animals_NNS
          (_( T_NN 13_CD /_NN OVX_NNP /_NN VEH_NNP )_) (_( Figure_NN 2_LS )_) ._. Furthermore_RB ,_, none_NN of_IN the_DT other_JJ
          trabecular_NN bone_NN parameters_NNS (_( Tb_NNP ._. Th_NNP ,_, Tb_NNP ._. Sp_NNP and_CC Tb_NNP ._. N_NNP )_)
          revealed_VBD a_DT significant_JJ difference_NN after_IN 13_CD weeks_NNS of_IN SVS_NNP
          treatment_NN when_WRB compared_VBN to_TO T_NN 13_CD /_NN OVX_NNP /_NN VEH_NNP animals_NNS ,_, (_( all_DT 
          P_NN =_SYM NS_NNP ,_, Table_NNP 2_LS )_) ._.
          Similarly_RB ,_, whole_JJ bone_NN volume_NN density_NN at_IN T_NN 13_CD was_VBD higher_JJR
          in_IN animals_NNS treated_VBN with_IN PTH_NNP compared_VBD to_TO the_DT OVX_NNP group_NN (_( 76_CD
          ±_NN 4_CD %_NN vs_NNS ._. 67_CD ±_NN 3_CD %_NN ,_, p_NN <_NN 0_CD ._. 001_CD )_) ,_, whereas_IN SVS_NNP treatment_NN
          had_VBD no_DT significant_JJ effect_NN (_( 68_CD ±_NN 3_CD %_NN vs_NNS ._. 67_CD ±_NN 3_CD %_NN ,_, p_NN =_SYM NS_NNP )_) ._.
          In_IN addition_NN ,_, cortical_JJ thickness_NN evaluated_VBN at_IN T_NN 13_CD was_VBD
          higher_JJR in_IN the_DT PTH_NNP treatment_NN group_NN compared_VBN to_TO the_DT OVX_NNP
          group_NN (_( 0_CD ._. 31_CD ±_NN 0_CD ._. 03_CD mm_NN vs_NNS ._. 0_CD ._. 26_CD ±_NN 0_CD ._. 02_CD mm_NN ,_, p_NN <_NN 0_CD ._. 001_CD )_) ,_,
          whereas_IN SVS_NNP treatment_NN exhibited_VBN no_DT effect_NN (_( 0_CD ._. 27_CD ±_NN 0_CD ._. 01_CD mm_NN
          vs_NNS ._. 0_CD ._. 26_CD ±_NN 0_CD ._. 02_CD mm_NN ,_, p_NN =_SYM NS_NNP ,_, Table_NNP 2_LS )_) ._.
        
        
          Osteocalcin_NNP
          Mean_VB serum_NN osteocalcin_NN (_( OC_NNP )_) of_IN SHAM_NNP and_CC OVX_NNP treated_VBD
          animals_NNS did_VBD not_RB change_VB significantly_RB when_WRB compared_VBN at_IN 1_CD ,_,
          5_CD and_CC 13_CD weeks_NNS ._. PTH_NNP treated_VBD mice_NNS ,_, however_RB revealed_VBD an_DT
          increase_NN (_( 596_CD ±_NN 138_CD ng_NN /_NN ml_NN )_) over_IN T_NN 13_CD /_NN OVX_NNP /_NN VEH_NNP animals_NNS (_( 252_CD
          ±_NN 57_CD ng_NN /_NN ml_NN ,_, 
          P_NN <_NN 0_CD ._. 001_CD ,_, Figure_NN 2_LS )_) ._. SVS_NNP
          treatment_NN at_IN 13_CD weeks_NNS ,_, however_RB ,_, caused_VBD no_DT significant_JJ
          increases_NNS in_IN OC_NNP compared_VBD to_TO T_NN 13_CD /_NN OVX_NNP /_NN VEH_NNP animals_NNS (_( 309_CD ±_NN 74_CD
          ng_NN /_NN ml_NN vs_NNS ._. 252_CD ±_NN 57_CD ng_NN /_NN ml_NN ,_, p_NN =_SYM NS_NNP ,_, Figure_NN 3_LS )_) ._.
        
        
          Detection_NNP of_IN the_DT active_JJ Simvastatin_NNP hydroxy_NN acid_NN
          metabolite_NN in_IN mouse_NN serum_NN after_IN gavage_NN
          administration_NN
          In_IN this_DT study_NN ,_, SVS_NNP was_VBD administered_VBN by_IN gavage_NN ,_, and_CC
          requires_VBZ hepatic_JJ conversion_NN to_TO the_DT metabolically_RB active_JJ
          β-hydroxy_JJ acid_NN (_( SVS-OH_NNP )_) ._. Because_IN SVS_NNP failed_VBD to_TO have_VB any_DT
          effect_NN on_IN any_DT static_JJ μCT_NN parameter_NN measured_VBN at_IN either_DT
          site_NN in_IN mouse_NN femur_NN ,_, we_PRP conducted_VBD separate_JJ experiments_NNS
          designed_VBN to_TO detect_VB the_DT presence_NN of_IN SVS-OH_NNP in_IN mouse_NN serum_NN
          after_IN SVS_NNP gavage_NN by_IN liquid_JJ chromatography_NN /_NN mass_NN
          spectrometry_NN (_( LC_NNP /_NN MS_NNP )_) ._.
          Reverse-phase_NNP high_JJ performance_NN liquid_JJ chromatography_NN
          (_( RP-HPLC_NNP )_) tandem_JJ electrospray_NN ionization_NN mass_NN
          spectrometry_NN (_( ESI-MS_NNP )_) method_NN published_VBN by_IN Wu_NNP et_CC al_NN ._. [_NN 15_CD
          ]_NN was_VBD used_VBN to_TO analyze_VB samples_NNS of_IN mouse_NN serum_NN for_IN the_DT
          presence_NN of_IN SVS_NNP and_CC SVS-OH_NNP ._. The_DT identity_NN of_IN the_DT eluted_JJ
          peak_NN in_IN RP-HPLC_NNP was_VBD established_VBN by_IN the_DT determination_NN of_IN
          the_DT mass_NN associated_VBN with_IN it_PRP by_IN ESI-MS_NNP ._. The_DT retention_NN
          times_NNS for_IN SVS_NNP and_CC SVS-OH_NNP were_VBD 19_CD ._. 5_LS ±_NN 0_CD ._. 5_CD and_CC 15_CD ._. 35_CD ±_NN 0_CD ._. 20_CD
          min_NN ,_, respectively_RB ._. Threshold_NNP of_IN detection_NN on_IN the_DT LC-MS_NNP at_IN
          λ_NN 
          240_CD nm_NN (_( AUFS_NNP =_SYM 0_CD ._. 1_LS )_) ,_, the_DT most_RBS
          sensitive_JJ wavelength_NN ,_, for_IN both_DT SVS_NNP and_CC the_DT SVS-OH_NNP was_VBD ~_NN 1_CD
          ng_NN ._. Calibration_NNP curves_NNS for_IN both_DT the_DT SVS_NNP and_CC the_DT SVS-OH_NNP
          extracted_VBD from_IN the_DT area_NN under_IN the_DT curve_NN in_IN the_DT HPLC_NNP
          profile_NN was_VBD linear_JJ in_IN the_DT range_NN of_IN 1_CD -_: 150_CD ng_NN ._. These_DT curves_NNS
          were_VBD used_VBN to_TO quantitate_NN the_DT drug_NN and_CC metabolite_NN levels_NNS in_IN
          mouse_NN plasma_NN ._. Based_VBN on_IN the_DT spiking_VBG of_IN mouse_NN plasma_NN 
          ex-vivo_JJ with_IN known_VBN amounts_NNS of_IN drug_NN
          and_CC subjecting_VBG the_DT samples_NNS for_IN the_DT extraction_NN procedure_NN ,_,
          the_DT efficiency_NN of_IN drugs_NNS recovery_NN was_VBD estimated_VBN to_TO be_VB
          60_CD -_: 75_CD %_NN for_IN SVS_NNP and_CC 70_CD -_: 85_CD %_NN for_IN SVS-OH_NNP ._. Figure_NN 4_CD is_VBZ a_DT
          representative_NN example_NN of_IN the_DT LC-MS_NNP analysis_NN of_IN a_DT sample_NN
          collected_VBN from_IN a_DT mouse_NN 30_CD min_NN after_IN treatment_NN with_IN 100_CD
          mg_NN /_NN kg_NN SVS_NNP ._. In_IN this_DT sample_NN both_DT the_DT RP-HPLC_NNP tracing_VBG and_CC
          the_DT ESI-MS_NNP analysis_NN of_IN the_DT peaks_NNS corresponding_JJ to_TO the_DT
          drug_NN and_CC its_PRP$ metabolite_NN confirm_VBP the_DT presence_NN of_IN both_DT in_IN
          the_DT serum_NN ._.
          Both_DT residual_JJ SVS_NNP and_CC its_PRP$ 
          in_IN situ_NN -_: generated_VBN metabolite_NN
          SVS-OH_NNP were_VBD detected_VBN in_IN the_DT mouse_NN plasma_NN as_RB early_RB as_IN 10_CD
          min_NN after_IN gavage_NN administration_NN of_IN 100_CD mg_NN /_NN kg_NN of_IN SVS_NNP (_( the_DT
          shortest_JJS sampling_VBG interval_NN )_) ._. The_DT levels_NNS of_IN SVS_NNP and_CC SVS-OH_NNP
          in_IN the_DT plasma_NN 10_CD min_NN after_IN administration_NN were_VBD 97_CD ._. 3_LS and_CC
          15_CD ._. 3_LS ng_NN /_NN μl_NN ,_, respectively_RB ._. These_DT findings_NNS establish_VB the_DT
          bioavailability_NN of_IN the_DT drug_NN following_VBG this_DT route_NN of_IN
          administration_NN ._.
        
      
      
        Discussion_NNP
        The_DT aim_NN of_IN this_DT study_NN was_VBD to_TO investigate_VB the_DT effect_NN of_IN
        Simvastatin_NNP on_IN bone_NN in_IN an_DT established_VBN mouse_NN model_NN of_IN
        osteoporosis_NNS ._. This_DT Swiss-_NNP Webster_NNP outbred_JJ mouse_NN strain_NN
        utilized_JJ in_IN this_DT study_NN has_VBZ proven_VBN to_TO be_VB a_DT valuable_JJ model_NN
        for_IN investigating_VBG the_DT efficacy_NN of_IN both_DT anabolic_JJ and_CC
        anti-resorptive_JJ therapies_NNS for_IN the_DT treatment_NN of_IN
        osteoporosis_NNS ._. Here_RB ,_, we_PRP have_VBP used_VBN PTH_NNP as_IN a_DT positive_JJ control_NN
        [_NN 11_CD ]_NN ,_, and_CC compared_VBD its_PRP$ effects_NNS to_TO SVS_NNP ._. While_IN PTH_NNP
        demonstrated_VBD the_DT expected_VBN anabolic_JJ effect_NN on_IN bone_NN ,_, SVS_NNP
        failed_VBD to_TO stimulate_VB bone_NN formation_NN ,_, despite_IN our_PRP$
        verification_NN by_IN LC_NNP /_NN MS_NNP of_IN the_DT active_JJ SVS-OH_NNP metabolite_NN in_IN
        mouse_NN serum_NN ._.
        The_DT SVS-OH_NNP metabolite_NN is_VBZ first_JJ detectable_JJ in_IN mouse_NN serum_NN
        by_IN 10_CD minutes_NNS after_IN gavage_NN administration_NN ,_, and_CC serum_NN levels_NNS
        of_IN SVS-OH_NNP continued_VBD to_TO be_VB observed_VBN by_IN both_DT
        mass-spectrometric_JJ and_CC UV_NNP measurements_NNS through_IN the_DT last_JJ
        serum_NN samples_NNS collected_VBN at_IN 50_CD minutes_NNS post-gavage_JJ ._. Other_JJ
        experiments_NNS failed_VBD to_TO detect_VB SVS-OH_NNP at_IN longer_JJR post-gavage_JJ
        timepoints_NNS of_IN 3_CD and_CC 24_CD hours_NNS ._. These_DT data_NNS are_VBP in_IN general_JJ
        agreement_NN with_IN studies_NNS in_IN both_DT rats_NNS and_CC canines_NNS that_WDT
        calculate_VBP peak_NN serum_NN levels_NNS of_IN SVS-OH_NNP at_IN 40_CD -_: 60_CD minutes_NNS
        after_IN gavage_NN administration_NN [_NN 18_CD ]_NN ._. Thus_RB ,_, although_IN we_PRP
        failed_VBD to_TO document_VB any_DT bone_NN anabolic_JJ activity_NN of_IN SVS_NNP in_IN a_DT
        mouse_NN model_NN of_IN OVX-induced_NNP osteoporosis_NNS ,_, LC_NNP /_NN MS_NNP analysis_NN of_IN
        the_DT SVS-OH_NNP metabolite_NN in_IN mouse_NN serum_NN document_NN the_DT efficacy_NN
        of_IN our_PRP$ gavage_NN administration_NN of_IN SVS_NNP to_TO experimental_JJ
        mice_NNS ._.
        Extrapolating_NNP from_IN mice_NNS to_TO humans_NNS ,_, the_DT dose_NN of_IN SVS_NNP
        administered_VBN in_IN this_DT study_NN was_VBD approximately_RB 400_CD -_: fold_VB
        higher_JJR than_IN the_DT average_JJ dose_NN given_VBN to_TO humans_NNS ._. The_DT results_NNS
        suggest_VBP that_IN Simvastatin_NNP does_VBZ not_RB enhance_VB bone_NN formation_NN in_IN
        this_DT mouse_NN model_NN 
        in_IN vivo_NN ,_, despite_IN our_PRP$ ability_NN to_TO
        verify_VB the_DT presence_NN of_IN the_DT SVS-OH_NNP metabolite_NN in_IN mouse_NN serum_NN
        by_IN LC_NNP /_NN MS_NNP analysis_NN ._. Furthermore_RB ,_, the_DT osteocalcin_NN assay_NN did_VBD
        not_RB suggest_VB any_DT increase_NN in_IN osteoblast_NN activity_NN in_IN SVS_NNP
        treated_VBD mice_NNS ,_, consistent_JJ with_IN its_PRP$ failure_NN to_TO increase_VB bone_NN
        density_NN ._.
        It_PRP is_VBZ generally_RB accepted_VBN that_IN the_DT hydroxy_NN acid_NN form_NN of_IN
        statins_NNS are_VBP potent_JJ inhibitors_NNS of_IN 3_CD -_: hydroxy-_NN 3_CD -_: methylglutaryl_NN
        coenzyme_NN A_DT (_( HMG-CoA_NNP )_) reductase_NN ,_, an_DT enzyme_NN that_WDT plays_VBZ a_DT
        critical_JJ role_NN in_IN cholesterol_NN metabolism_NN ,_, where_WRB they_PRP block_VBP
        substrate_NN accessibility_NN to_TO HMG-CoA_NNP reductase_NN ,_, effectively_RB
        subverting_VBG cholesterol_NN levels_NNS of_IN HDL_NNP [_NN 19_CD 20_CD 21_CD ]_NN ._. In_IN
        addition_NN to_TO lowering_VBG cholesterol_NN ,_, statins_NNS seem_VBP to_TO have_VB a_DT
        number_NN of_IN additional_JJ effects_NNS ,_, such_JJ as_IN the_DT nitric_JJ
        oxide-mediated_JJ promotion_NN of_IN new_JJ blood_NN vessel_NN growth_NN [_NN 22_CD ]_NN
        ,_, protection_NN against_IN oxidative_JJ modification_NN of_IN low-density_NN
        lipoprotein_NN ,_, as_RB well_RB as_IN anti-inflammatory_JJ effects_NNS and_CC a_DT
        reduction_NN in_IN C-_NNP reactive_JJ protein_NN levels_NNS [_NN 23_CD ]_NN ._. All_DT statins_NNS
        limit_VBP cholesterol_NN biosynthesis_NNS by_IN inhibiting_VBG the_DT committed_VBN
        step_NN in_IN the_DT biosynthesis_NNS of_IN isoprenoids_NNS and_CC sterols_NNS [_NN 24_CD ]_NN
        ._.
        Considering_VBG the_DT enormous_JJ potential_JJ impact_NN of_IN statins_NNS on_IN
        the_DT treatment_NN of_IN osteoporosis_NNS ,_, several_JJ groups_NNS have_VBP further_RBR
        investigated_VBN the_DT skeletal_NN effects_NNS of_IN statin_NN use_NN ._. Several_JJ
        groups_NNS have_VBP failed_VBN to_TO confirm_VB the_DT initially_RB reported_VBN
        anabolic_JJ effect_NN of_IN systemically_RB administered_VBN statins_NNS 
        in_IN vivo_NN in_IN rats_NNS [_NN 25_CD 26_CD 27_CD ]_NN ._. One_CD
        obvious_JJ criticism_NN of_IN the_DT negative_JJ data_NN in_IN these_DT studies_NNS is_VBZ
        that_IN they_PRP did_VBD not_RB verify_VB the_DT actual_JJ presence_NN of_IN statin_NN in_IN
        the_DT animal_NN serum_NN ._. This_DT limitation_NN may_MD be_VB of_IN importance_NN ,_, as_IN
        Crawford_NNP et_CC al_NN [_NN 27_CD ]_NN could_MD detect_VB an_DT increase_NN in_IN cortical_JJ
        bone_NN when_WRB statin_NN was_VBD administered_VBN locally_RB ._. Our_PRP$ study_NN
        demonstrated_VBD the_DT presence_NN of_IN systemically_RB administered_VBN the_DT
        SVS-OH_NNP metabolite_NN in_IN the_DT mouse_NN serum_NN by_IN LC_NNP /_NN MS_NNP analysis_NN ._.
        The_DT exact_JJ mechanism_NN by_IN which_WDT statins_NNS perform_VBP their_PRP$
        effects_NNS on_IN bone_NN cell_NN function_NN is_VBZ a_DT central_JJ issue_NN ._. It_PRP has_VBZ
        been_VBN hypothesized_VBN that_IN statins_NNS mediate_VB their_PRP$ effects_NNS by_IN
        increasing_VBG the_DT expression_NN in_IN bone_NN of_IN the_DT growth_NN factor_NN bone_NN
        morphogenic_JJ protein-_NN 2_CD (_( BMP-_NNP 2_LS )_) which_WDT in_IN turn_NN leads_VBZ to_TO
        osteoblast_NN differentiation_NN and_CC bone_NN formation_NN [_NN 2_CD ]_NN ._. This_DT
        mechanism_NN of_IN action_NN has_VBZ been_VBN addressed_VBN by_IN Baumann_NNP et_CC al_NN ._. in_IN
        rats_NNS ,_, where_WRB the_DT anabolic_JJ effect_NN of_IN lovastatin_NN on_IN bone_NN was_VBD
        at_IN least_JJS partially_RB due_JJ to_TO their_PRP$ inhibiting_VBG effect_NN on_IN
        osteoclast_NN development_NN [_NN 28_CD ]_NN ._. Similarly_RB ,_, in_IN the_DT mouse_NN
        calvaria_NN model_NN Gasser_NNP et_CC al_NN ._. failed_VBD to_TO detect_VB any_DT anabolic_JJ
        activity_NN of_IN statins_NNS in_IN bone_NN and_CC suggested_VBD that_IN the_DT
        disruption_NN of_IN the_DT capillary_JJ integrity_NN and_CC local_NN bleeding_NN
        might_MD explain_VB some_DT of_IN the_DT previously_RB reported_VBN bone_NN
        responses_NNS [_NN 26_CD ]_NN ._.
        Several_JJ studies_NNS in_IN humans_NNS reported_VBD a_DT decreased_VBN risk_NN of_IN
        fracture_NN after_IN statin_NN treatment_NN [_NN 3_CD 29_CD 30_CD ]_NN ._. However_RB
        larger_JJR human_JJ studies_NNS failed_VBD to_TO confirm_VB statins_NNS beneficial_JJ
        effect_NN on_IN bone_NN ._. LaCroix_NNP et_CC al_NN ._. found_VBD the_DT risk_NN of_IN hip_NN and_CC
        arm_NN fracture_NN to_TO be_VB similar_JJ among_IN women_NNS who_WP used_VBD statins_NNS and_CC
        those_DT who_WP did_VBD not_RB take_VB lipid_NN lowering_VBG medication_NN [_NN 31_CD ]_NN ._.
        Van_NNP Staa_NNP et_CC al_NN ._. examining_VBG 218_CD ,_, 062_CD individuals_NNS with_IN a_DT
        fracture_NN in_IN the_DT General_NNP Practice_NNP Database_NNP in_IN the_DT United_NNP
        Kingdom_NNP ,_, and_CC found_VBD no_DT relationship_NN between_IN statin_NN use_NN and_CC
        nonspine_NN fracture_NN [_NN 32_CD ]_NN ._. Interestingly_RB ,_, a_DT report_NN by_IN Meier_NNP
        [_NN 3_CD ]_NN had_VBD used_VBN the_DT exact_JJ same_JJ database_NN as_IN van_NN Staa_NNP et_CC al_NN ._. [_NN
        32_CD ]_NN ,_, but_CC sampled_VBN a_DT much_RB larger_JJR cohort_NN (_( 218_CD ,_, 062_CD
        individuals_NNS with_IN fracture_NN )_) than_IN Meier_NNP (_( 3940_CD )_) ,_, and_CC in_IN
        addition_NN ,_, selected_VBD an_DT age_NN and_CC gender_NN matched_VBD control_NN
        patient_NN for_IN every_DT fracture_NN patient_NN ._. The_DT clinical_JJ data_NN
        available_JJ at_IN the_DT moment_NN does_VBZ not_RB allow_VB the_DT conclusion_NN that_DT
        statin_NN treatment_NN has_VBZ a_DT postive_JJ relationship_NN with_IN fracture_NN
        risk_NN ._.
        Similarly_RB as_IN described_VBN in_IN the_DT clinical_JJ trials_NNS ,_, the_DT early_JJ
        animal_NN studies_NNS reported_VBD data_NNS supportive_JJ of_IN the_DT initial_JJ
        findings_NNS [_NN 1_CD 4_CD 5_CD 6_CD 33_CD 34_CD ]_NN ._. These_DT results_NNS however_RB ,_, were_VBD
        not_RB substantiated_JJ in_IN later_JJ studies_VBZ in_IN rodents_NNS ,_, where_WRB SVS_NNP
        had_VBD no_DT or_CC little_JJ effect_NN on_IN bone_NN mineral_NN density_NN [_NN 26_CD ]_NN ._.
        However_RB ,_, none_NN of_IN the_DT studies_NNS has_VBZ verified_VBN the_DT actual_JJ
        presence_NN of_IN the_DT active_JJ SVS-OH_NNP metabolite_NN in_IN the_DT animal_NN
        serum_NN ,_, as_IN shown_VBN in_IN this_DT study_NN ._. In_IN combination_NN with_IN the_DT
        osteocalcin_NN data_NN ,_, this_DT report_NN provides_VBZ strong_JJ evidence_NN that_DT
        simvastatin_NN does_VBZ not_RB have_VB an_DT effect_NN on_IN bone_NN in_IN an_DT
        established_VBN Swiss_NNP Webster_NNP mouse_NN model_NN of_IN OVX-induced_NNP
        osteoporosis_NNS ._.
      
      
        Conclusion_NNP
        In_IN summary_NN ,_, the_DT currently_RB available_JJ data_NNS on_IN the_DT effects_NNS
        of_IN statins_NNS on_IN bone_NN has_VBZ done_VBN little_JJ to_TO confirm_VB the_DT finding_VBG
        that_DT statin_NN therapy_NN increases_NNS bone_NN mass_NN and_CC thereby_RB lowers_VBZ
        fracture_NN risk_NN ._. Few_JJ of_IN the_DT studies_NNS in_IN animals_NNS and_CC humans_NNS
        have_VBP been_VBN able_JJ to_TO show_VB a_DT predictable_JJ beneficial_JJ effect_NN on_IN
        bone_NN mass_NN and_CC bone_NN turnover_NN ._. This_DT report_NN verifies_NNS the_DT
        presence_NN of_IN the_DT active_JJ SVS-OH_NNP metabolite_NN in_IN the_DT mouse_NN serum_NN
        yet_RB failed_VBD to_TO demonstrate_VB any_DT beneficial_JJ effect_NN on_IN bone_NN ._.
        While_IN statins_NNS have_VBP clear_JJ effects_NNS on_IN bone_NN formation_NN 
        in_IN vitro_NN ,_, the_DT formulation_NN of_IN
        existing_VBG '_POS liver-targeted_JJ '_POS statins_NNS may_MD require_VB further_JJ
        refinement_NN for_IN efficacy_NN on_IN bone_NN formation_NN 
        in_IN vivo_NN ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Authors_NNP contributions_NNS
        D_NNP ._. von_NNP Stechow_NNP :_: participated_VBD in_IN the_DT study_NN coordination_NN ,_,
        perfomed_JJ the_DT microCT_NN analysis_NN and_CC drafted_VBD the_DT
        manuscript_NN
        S_NNP ._. Fish_NN :_: carried_VBD out_RP the_DT animal_NN experiments_NNS
        D_NNP ._. Yahalom_NNP :_: carried_VBD out_RP the_DT mass_NN spec_NN analsysis_NNS
        I_PRP ._. Bab_NNP :_: participated_VBD in_IN the_DT design_NN of_IN the_DT study_NN
        M_NNP ._. Chorev_NNP :_: participated_VBD in_IN the_DT mass_NN spec_NN analysis_NN
        R_NN ._. Müller_NNP :_: participated_VBD in_IN the_DT microCT_NN analysis_NN
        J_NNP ._. M_NNP ._. Alexander_NNP :_: conceived_VBD of_IN the_DT study_NN ,_, and_CC
        participated_VBD in_IN its_PRP$ design_NN and_CC coordination_NN ,_, and_CC edited_JJ the_DT
        manuscript_NN
      
    
  
